{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-216321","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.677839+00:00","generated_at":"2026-05-31T05:39:06.607080+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viridian's veligrotug Phase 3 THRIVE meets all endpoints; 70% proptosis responder rate vs 5% placebo (p<0.0001)","bullets":["Proptosis responder rate 70% drug vs 5% placebo; mean reduction 2.9 mm vs 0.5 mm (p<0.0001).","Complete diplopia resolution 54% vs 12%; CAS 0/1 achieved by 64% vs 18% (both p<0.0001).","No treatment-related serious AEs; 5.5% placebo-adjusted hearing impairment rate; 4% discontinuation rate.","THRIVE-2 enrollment complete; topline data year-end 2024; BLA submission on track for 2H 2025.","Cash $571.4M as of June 30, 2024; runway into 2H 2026; VRDN-003 phase 3 REVEAL trials initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-216321","json":"https://secwatch.observer/filing/0001193125-24-216321.json","markdown":"https://secwatch.observer/filing/0001193125-24-216321.md","text":"https://secwatch.observer/filing/0001193125-24-216321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524216321/0001193125-24-216321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524216321/d885072d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:39:06.607080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}